Mario Antonini

Mario Antonini

Auto-generated profile, based on publicly available information

Mario Antonini

Anesthesiology and Intensive Care Unit, National Institute for Infectious Disease "L. Spallanzani", Rome, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
Nicola PetrosilloNicola Petrosillo
Nicola Petrosillo
Maddalena GiannellaMaddalena Giannella
Maddalena Giannella
MAMassimo Antonelli
Massimo Antonelli
MAMario Antonini
Mario Antonini
BBBruno Barsic
Bruno Barsic
Murat AkovaMurat Akova
Murat Akova
A colistin-glycopeptide combination (CGC) has been shown in vitro to be synergistic against multidrug-resistant Gram-negative bacteria (MDR GNB), especially Acinetobacter baumannii , and to prevent further resistance. However, clinical data are lacking. We carried out a retrospective multicenter study of patients hospitalized in intensive care units (ICUs) who received colistin for GNB infection over a 1-year period, to assess the rates of nephrotoxicity and 30-day mortality after treatment onset among patients treated with and without CGC for ≥48 h. Of the 184 patients treated with colistin, GNB infection was documented for 166. The main causative agents were MDR A. baumannii (59.6%), MDR Pseudomonas aeruginosa (18.7%), and carbapenem-resistant Klebsiella pneumoniae (14.5%); in 16.9% of patients, a Gram-positive bacterium (GPB) coinfection was documented. Overall, 68 patients (40.9%) received CGC. Comparison of patients treated with and without CGC showed significant differences for respiratory failure (39.7% versus 58.2%), ventilator-associated pneumonia (54.4% versus 71.4%), MDR A. baumannii infection (70.6% versus 52%), and GPB coinfection (41.2% versus 0%); there were no differences for nephrotoxicity (11.8% versus 13.3%) and 30-day mortality (33.8% versus 29.6%). Cox analysis performed on patients who survived for ≥5 days after treatment onset showed that the Charlson index (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.01 to 1.44; P = 0.001) and MDR A. baumannii infection (HR, 2.51; 95% CI, 1.23 to 5.12; P = 0.01) were independent predictors of 30-day mortality, whereas receiving CGC for ≥5 days was a protective factor (HR, 0.42; 95% CI, 0.19 to 0.93; P = 0.03). We found that CGC was not associated with higher nephrotoxicity and was a protective factor for mortality if administered for ≥5 days.

1 July 1999 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
ESEnrico Sbarigia
Enrico Sbarigia
CVCarmine Dario Vizza
Carmine Dario Vizza
MAMario Antonini
Mario Antonini
FSFrancesco Speziale
Francesco Speziale
MMMicaela Maritti
Micaela Maritti
PFPaolo Fiorani
Paolo Fiorani

1 November 2004 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
MAM. Albers
M. Albers
MRM. Romiti
M. Romiti
Carlos De Bragança PereiraCarlos De Bragança Pereira
Carlos De Bragança Pereira
MAM. Antonini
M. Antonini
MWM. Wulkan
M. Wulkan

5 August 2016 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre
GSGiovanni Battista Levi Sandri
Giovanni Battista Levi Sandri
ALAndrea Laurenzi
Andrea Laurenzi
MCMarco Colasanti
Marco Colasanti
RMRoberto Luca Meniconi
Roberto Luca Meniconi
GVGiovanni Vennarecci
Giovanni Vennarecci

1 January 1997 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
PFP. Fiorani
P. Fiorani
ESE. Sbarigia
E. Sbarigia
FSF. Speziale
F. Speziale
MAM. Antonini
M. Antonini
BFB. Fiorani
B. Fiorani
MMM. Massucci
M. Massucci

1 September 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
CAChiara Agrati
Chiara Agrati
CGCristiana Gioia
Cristiana Gioia
ELEleonora Lalle
Eleonora Lalle
ECEleonora Cimini
Eleonora Cimini
CCConcetta Castilletti
Concetta Castilletti
FMFederico Martini
Federico Martini
Background. Pandemic A/H1N1v influenza is characterized by a mild clinical course. However, a small subset of patients develops a rapidly progressive